Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review

Jinghong Liang, Jiayu Li, Ruixia Jia, Yingquan Wang, Rongkun Wu, Hongbo Zhang, Lei Hang, Yong Xu Department of Child Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, School of Public Health, Soochow University, Suzhou, China Purpose: The increasing pr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Liang JH, Li JY, Jia RX, Wang YQ, Wu RK, Zhang HB, Hang L, Xu Y
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://doaj.org/article/7f2e7222cdfa4ae0adcca28964972a0e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7f2e7222cdfa4ae0adcca28964972a0e
record_format dspace
spelling oai:doaj.org-article:7f2e7222cdfa4ae0adcca28964972a0e2021-12-02T03:17:27ZIdentification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review1178-1998https://doaj.org/article/7f2e7222cdfa4ae0adcca28964972a0e2018-10-01T00:00:00Zhttps://www.dovepress.com/identification-of-the-optimal-cognitive-drugs-among-alzheimers-disease-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Jinghong Liang, Jiayu Li, Ruixia Jia, Yingquan Wang, Rongkun Wu, Hongbo Zhang, Lei Hang, Yong Xu Department of Child Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, School of Public Health, Soochow University, Suzhou, China Purpose: The increasing prevalence of Alzheimer’s disease (AD) demands more effective drugs, which are still unclear. The aim of this study is to compare the effectiveness of six drugs, such as donepezil, rivastigmine, galantamine, memantine, huperzine-A, and tacrine, in senior AD patients and identify the most effective one to improve patients’ cognitive function.Methods: A system of search strategies was used to identify relevant studies including randomized controlled trials and clinical controlled trials evaluating the efficacy of six drugs in patients with AD. We updated relevant studies that were published before March 2018 as full-text articles. Using Bayesian network meta-analysis (NMA), we ranked cognitive ability objectively based on Mini–Mental State Examination (MMSE). Pairwise and NMAs were sequentially performed for the efficacy of drugs compared to each drug or control group through the trials included.Results: Among the 35 trials included, no obvious heterogeneity (I2=0.0%, P=0.583) was revealed according to the pooled data for cognition in NMA and the mean difference (MD) of memantine (MD=1.7, 95% CI: 0.73, 2.8) showed that the memantine was significantly efficacious in the treatment group in terms of MMSE. Followed by galantamine, huperzine-A, rivastigmine, tacrine, and donepezil.Conclusion: As the first NMA comparing the major drugs in market for AD, our study suggests that memantine might have a more significant benefit on cognition than other five drugs available. Keywords: Alzheimer’s disease, cognitive drugs, Bayesian network meta-analysisLiang JHLi JYJia RXWang YQWu RKZhang HBHang LXu YDove Medical PressarticleAlzheimer’s diseasecognitive drugsBayesian network meta-analysisGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 13, Pp 2061-2073 (2018)
institution DOAJ
collection DOAJ
language EN
topic Alzheimer’s disease
cognitive drugs
Bayesian network meta-analysis
Geriatrics
RC952-954.6
spellingShingle Alzheimer’s disease
cognitive drugs
Bayesian network meta-analysis
Geriatrics
RC952-954.6
Liang JH
Li JY
Jia RX
Wang YQ
Wu RK
Zhang HB
Hang L
Xu Y
Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review
description Jinghong Liang, Jiayu Li, Ruixia Jia, Yingquan Wang, Rongkun Wu, Hongbo Zhang, Lei Hang, Yong Xu Department of Child Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, School of Public Health, Soochow University, Suzhou, China Purpose: The increasing prevalence of Alzheimer’s disease (AD) demands more effective drugs, which are still unclear. The aim of this study is to compare the effectiveness of six drugs, such as donepezil, rivastigmine, galantamine, memantine, huperzine-A, and tacrine, in senior AD patients and identify the most effective one to improve patients’ cognitive function.Methods: A system of search strategies was used to identify relevant studies including randomized controlled trials and clinical controlled trials evaluating the efficacy of six drugs in patients with AD. We updated relevant studies that were published before March 2018 as full-text articles. Using Bayesian network meta-analysis (NMA), we ranked cognitive ability objectively based on Mini–Mental State Examination (MMSE). Pairwise and NMAs were sequentially performed for the efficacy of drugs compared to each drug or control group through the trials included.Results: Among the 35 trials included, no obvious heterogeneity (I2=0.0%, P=0.583) was revealed according to the pooled data for cognition in NMA and the mean difference (MD) of memantine (MD=1.7, 95% CI: 0.73, 2.8) showed that the memantine was significantly efficacious in the treatment group in terms of MMSE. Followed by galantamine, huperzine-A, rivastigmine, tacrine, and donepezil.Conclusion: As the first NMA comparing the major drugs in market for AD, our study suggests that memantine might have a more significant benefit on cognition than other five drugs available. Keywords: Alzheimer’s disease, cognitive drugs, Bayesian network meta-analysis
format article
author Liang JH
Li JY
Jia RX
Wang YQ
Wu RK
Zhang HB
Hang L
Xu Y
author_facet Liang JH
Li JY
Jia RX
Wang YQ
Wu RK
Zhang HB
Hang L
Xu Y
author_sort Liang JH
title Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review
title_short Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review
title_full Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review
title_fullStr Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review
title_full_unstemmed Identification of the optimal cognitive drugs among Alzheimer’s disease: a Bayesian meta-analytic review
title_sort identification of the optimal cognitive drugs among alzheimer’s disease: a bayesian meta-analytic review
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/7f2e7222cdfa4ae0adcca28964972a0e
work_keys_str_mv AT liangjh identificationoftheoptimalcognitivedrugsamongalzheimerrsquosdiseaseabayesianmetaanalyticreview
AT lijy identificationoftheoptimalcognitivedrugsamongalzheimerrsquosdiseaseabayesianmetaanalyticreview
AT jiarx identificationoftheoptimalcognitivedrugsamongalzheimerrsquosdiseaseabayesianmetaanalyticreview
AT wangyq identificationoftheoptimalcognitivedrugsamongalzheimerrsquosdiseaseabayesianmetaanalyticreview
AT wurk identificationoftheoptimalcognitivedrugsamongalzheimerrsquosdiseaseabayesianmetaanalyticreview
AT zhanghb identificationoftheoptimalcognitivedrugsamongalzheimerrsquosdiseaseabayesianmetaanalyticreview
AT hangl identificationoftheoptimalcognitivedrugsamongalzheimerrsquosdiseaseabayesianmetaanalyticreview
AT xuy identificationoftheoptimalcognitivedrugsamongalzheimerrsquosdiseaseabayesianmetaanalyticreview
_version_ 1718401866062102528